Six-month sirtuin activator supplementation for women with overweight or obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Women aged 40–65 with BMI over 25 will take either a sirtuin activator supplement or a placebo each day for six months. Researchers will compare the two groups on lipid and carbohydrate metabolism as well as measures of oxidative stress, immune function, and cellular ageing. Participants will visit the university every three months for checkups and laboratory tests. The study compares outcomes between the supplement and placebo arms to determine whether the supplement produces measurable metabolic improvements.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* females
* age: 40-65 years
* overweight or obese: BMI \>25 kg/m2

Exclusion Criteria:

* males
* BMI \< 25 kg/m2
* sirtuin activators administration for 3 months prior to study
* pregnancy or breastfeeding
* recent dieting or being on calorie restricted diet
* receiving pharmacotherapy to treat obesity, diabetes or hyperlipidemia
* post-bariatric surgery
* diabetes
* cancer
* chronic kidney, liver or autoimmune diseases
* alcohol addiction

Where it's running

• Poznan University of Life Sciences
  Poznan, Poland Recruiting

Study contacts

• Principal investigator: Agata Chmurzynska, Professor — Poznan Univeristy of Life Sciences
• Study coordinator: Agata Chmurzynska, Professor
• Email: agata.chmurzynska@up.poznan.pl
• Phone: +486184661

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How incretin treatments affect muscle mass and function in people with overweight or obesity

  This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.

  Recruiting Radboud University Medical Center · Amsterdam and 1 other locations · NCT07929831

• Dose find for remimazolam plus alfentanil for gastroscopy in obese adults

  This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07925684

• Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults

  This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.

  Recruiting Yuzuncu Yil University · Van · NCT07901777

• Gut barrier and inflammation after fast-food overfeeding in adults

  This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup · NCT07893743

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• GLP-1 weight‑loss medicine: finding who will benefit most

  This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.

  Recruiting Phase 4 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07870538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.